Ixaka Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Subsidiary
- Established
- 2015-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.ixaka.com
Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 3
2 (100.0%)The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM
Phase 3
Terminated
- Conditions
- Peripheral Arterial Disease (PAD)Diabetes Mellitus (DM)Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Cardiovascular DiseaseCritical Limb Ischemia (CLI)
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-06-02
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- Ixaka Ltd
- Target Recruit Count
- 49
- Registration Number
- NCT03174522
- Locations
- 🇨🇿
Fakultní nemocnice Ostrava, Ostrava, Czechia
🇭🇺Pécsi Tudományegyetem, PTE-KK I. sz Belgyógyászati Klinika, Pécs, Hungary
🇳🇱Leids Universitair Medisch Centrum, Leiden, Netherlands
The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM
Phase 3
Terminated
- Conditions
- Peripheral Arterial Disease (PAD)Diabetes Mellitus, Type 1Critical Limb Ischemia (CLI)Diabetes Mellitus (DM)Diabetes Mellitus, Type 2Cardiovascular Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2021-05-07
- Lead Sponsor
- Ixaka Ltd
- Target Recruit Count
- 3
- Registration Number
- NCT03111238
- Locations
- 🇨🇿
Fakultní nemocnice Ostrava, Ostrava, Czechia
🇨🇿Vitkovicka nemocnice a. s. Vaskularni centrum, Ostrava, Czechia
🇩🇪Klinikum der Goethe-Universität Frankfurt, Frankfurt, Germany
News
No news found